Rapid Pathogen Screening appointed Caroline Popper, M.D., and Hanjoon Ryu to its board of directors...Synthetic Biologics named Charles B. Shoemaker, Ph.D., to its scientific advisory board...Nabsys added Peter Lewis as CFO and Darren Lee as vp, business development...Advanced Clinical hired Susan Seroskie as evp, strategic resourcing.
Richard Flavell, Ph.D., is now chief scientific advisor at Ceres...Silence Therapeutics added Tim Freeborn as its finance director...Corcept Therapeutics appointed Daniel M. Bradbury to its board of directors...Genome Canada named Lorne Hepworth chair of its board of directors...Henry Lenz, Ph.D., joined TNI BioTech as quality control officer.
Rosetta Genomics added E. Robert Wassman, M.D., as CMO and Dganit Bar, Ph.D., as CSO...Zyngenia appointed Jason Rhodes to its board of directors...Christian Weyer is now president and CEO at Fate Therapeutics...Rheonix appointed Bill Colston, Ph.D., to its board of directors...Cerecor hired James Vornov, M.D. Ph.D., as svp, clinical development and regulatory affairs and John Kaiser as vp of commercialization and business development.
Sequenom added Bill Bowen as svp and general counsel...LabCorp appointed Peter M. Neupert to its board of directors...Vital Connect named Neal White, M.D., to its medical advisory board...NanoBio promoted David Peralta to CEO...Oramed Pharmaceuticals appointed Gerald Ostrov to its board of directors...Jeffrey Nieman joined Cymetrix as svp, remote operations...Sirona Biochem added Nigel Terrett as strategic advisor.
MYOS hired Andrew J. Einhorn as CFO...Jonathan Turner, Ph.D., is now managing director and CEO of caprotec bioanalytics...LifeMap Sciences appointed Louis E. Silverman to its board of directors...NovAliX hired Luc Van Hijfte, Ph.D., as CSO drug discovery...Sanford-Burnham named Dwight A. Towler, M.D., Ph.D., director of its cardiovascular pathobiology program.
CSR Pharma Services appointed Michael Dubois, Eric Sheinen, Ph.D., and Wendy Stephenson, M.D., to its scientific and FDA board and Caroline Wang and Phoebe Yeh to its board of directors...Omeros added Cathy Melfi, Ph.D., as vp of regulatory affairs and quality systems and Albert Yu, M.D., as vp of clinical development...Amarantus BioSciences appointed Clinton O. Allen to its advisory board.